Results 11 to 20 of about 9,805,880 (332)

Current Understanding of Clinical Manifestations of COVID-19 in Glomerular Disease

Glomerular Diseases, 2021
Background: The novel coronavirus disease (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an evolving pandemic with significant mortality. Information about the impact of infection on glomerular disease patients
Allison Shimmel, Salma Shaikhouni, L. Mariani   +2 more
semanticscholar   +1 more source

Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. [PDF]

, 2015
Trial designThis analysis characterizes the degree of early organ involvement in a cohort of oligo-symptomatic untreated young patients with Fabry disease enrolled in an ongoing randomized, open-label, parallel-group, phase 3B clinical trial.MethodsMales
An Haack, Kristina, Bichet, Daniel G, Bénichou, Bernard, Clarke, Lorne A, Dostalova, Gabriela, Fainboim, Alejandro, Fellgiebel, Andreas, Forcelini, Cassiano, Hopkin, Robert J, Mauer, Michael, Najafian, Behzad, Ramaswami, Uma, Scott, C Ronald, Shankar, Suma P, Thurberg, Beth L, Tylki-Szymańska, Anna, Tøndel, Camilla, Wijburg, Frits A   +17 more
core   +8 more sources

Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases

Case Reports in Nephrology and Dialysis, 2022
There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-
Craig Peter Coorey, Elaine Phua, Angela Chou, Yvonne Shen, Amanda Mather   +4 more
doaj   +1 more source

Associations of Podocyte-Derived Protein Biomarkers With Foot Process Effacement and Kidney Histopathologic Lesions in Individuals With Glomerular Disease [PDF]

Kidney Medicine
Insa M. Schmidt, MD, MPH, Ashish Verma, MD, Sophie Claudel, MD, Sophia Rosan, BA, Weining Lu, MD, MS, Laurence H. Beck, Jr., MD, PhD, Courtney Huynh, MS, Ragnar Palsson, MD, Anand Srivastava, MD, MPH, Isaac Stillman, MD, Claire Avillach, MD, Tobias B. Huber, MD, Jessica Volpe, PhD, Carlos Morales Betanzos, PhD, Mireia Fernandez Ocana, PhD, Stephen P. Berasi, PhD, Kelly Alana Fader, PhD, Mohamed Hassanein, PhD, Sushrut S. Waikar, MD, MPH   +18 more
doaj   +2 more sources

COVID-19-Associated Glomerular Disease.

Journal of the American Society of Nephrology, 2020
BACKGROUND Studies have documented AKI with high-grade proteinuria in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Aneesha Shetty, Ibrahim Tawhari, Luisa Safar-Boueri, Nay Seif, Ameen S. Alahmadi, R. Gargiulo, Vikram Aggarwal, Irtaza Usman, S. Kisselev, A. Gharavi, Y. Kanwar, S. Quaggin   +11 more
semanticscholar   +1 more source

Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management

Diagnostics, 2021
Randall-type monoclonal immunoglobulin deposition disease (MIDD) is a rare disease that belongs to the spectrum of monoclonal gammopathy of renal significance (MGRS).
Camille Cohen, Florent Joly, Audrey Sibille, Vincent Javaugue, Estelle Desport, Jean-Michel Goujon, Guy Touchard, Jean-Paul Fermand, Christophe Sirac, Frank Bridoux   +9 more
doaj   +1 more source

Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression.

Journal of Clinical Investigation, 2020
Utilizing the Nephrotic Syndrome Study Network Consortium and other publicly available transcriptomic datasets, we identified Retinoic acid receptor responder protein 1 (RARRES1) as a gene whose expression positively correlated with renal function ...
Anqun Chen, Ye Feng, Han Lai, W. Ju, Zhengzhe Li, Y. Li, Andrew Wang, Quan Hong, F. Zhong, Chengguo Wei, Jia Fu, Tian-Jun Guan, Bi-Cheng Liu, M. Kretzler, Kyung Lee, J. He   +15 more
semanticscholar   +1 more source

Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers.

American Society of Nephrology. Clinical Journal, 2020
BACKGROUND AND OBJECTIVES Shared decision making in patients with glomerular disease remains challenging because outcomes important to patients remain largely unknown.
S. Carter, Talia Gutman, C. Logeman, D. Cattran, L. Lightstone, A. Bagga, S. Barbour, Jonathan Barratt, J. Boletis, Dawn J. Caster, R. Coppo, F. Fervenza, J. Floege, M. Hladunewich, Jonathan J. Hogan, A. Kitching, R. Lafayette, A. Malvar, J. Radhakrishnan, B. Rovin, N. Scholes-Robertson, H. Trimarchi, Hong Zhang, K. Ažukaitis, Yeoungjee Cho, A. Viecelli, Louese Dunn, D. Harris, David W. Johnson, P. Kerr, P. Laboi, J. Ryan, Jenny I. Shen, L. Ruiz, A. Wang, A. Lee, Samuel Fung, M. Tong, A. Teixeira-Pinto, M. Wilkie, S. Alexander, J. Craig, A. Tong   +42 more
semanticscholar   +1 more source

Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis [PDF]

, 2017
IgA nephropathy (IgAN) is the most prevalent among primary glomerular diseases worldwide. Although our understanding of IgAN has advanced significantly, its underlying biology and potential drug targets are still unexplored.
Cisek, Katryna, Delles, Christian, Filip, Szymon, Gakiopoulou, Chara, Jankowski, Joachim, Krochmal, Magdalena, Markoska, Katerina, Mischak, Harald, Orange, Clare, Spasovski, Goce, Vlahou, Antonia, Zoidakis, Jerome   +11 more
core   +2 more sources

Hyperglycemia and Hyperlipidemia Act Synergistically to Induce Renal Disease in LDL Receptor-Deficient BALB Mice [PDF]

, 2004
Diabetic nephropathy is the leading cause of end-stage renal disease in Western countries, but only a portion of diabetic patients develop diabetic nephropathy.
Alpers, Charles E., Hudkins, Kelly L., Kirk, Elizabeth, LeBoeuf, Renée C., Mühlfeld, Anja S., Segerer, Stephan, Spencer, Min W.   +6 more
core   +1 more source